OBJECTIVES: The aim of this study was to evaluate the cost-effectiveness in liver transplantation (LT) of utilizing organs donated after cardiac death (DCD) compared with organs donated after brain death (DBD). METHODS: A Markov-based decision analytic model was created to compare two LT waitlist strategies distinguished by organ type: (i) DBD organs only, and (ii) DBD and DCD organs. The model simulated outcomes for patients over 10 years with annual cycles through one of four health states: survival; ischaemic cholangiopathy; retransplantation, and death. Baseline values and ranges were determined from an extensive literature review. Sensitivity analyses tested model strength and parameter variability. RESULTS: Overall survival is decreased, and biliary complications and retransplantation are increased in recipients of DCD livers. Recipients of DBD livers gained 5.6 quality-adjusted life years (QALYs) at a cost of US$69 000/QALY, whereas recipients on the DBD + DCD LT waitlist gained 6.0 QALYs at a cost of US$61 000/QALY. The DBD + DCD organ strategy was superior to the DBD organ-only strategy. CONCLUSIONS: The extension of life and quality of life provided by DCD LT to patients on the waiting list who might otherwise not receive a liver transplant makes the continued use of DCD livers cost-effective.
OBJECTIVES: The aim of this study was to evaluate the cost-effectiveness in liver transplantation (LT) of utilizing organs donated after cardiac death (DCD) compared with organs donated after brain death (DBD). METHODS: A Markov-based decision analytic model was created to compare two LT waitlist strategies distinguished by organ type: (i) DBD organs only, and (ii) DBD and DCD organs. The model simulated outcomes for patients over 10 years with annual cycles through one of four health states: survival; ischaemic cholangiopathy; retransplantation, and death. Baseline values and ranges were determined from an extensive literature review. Sensitivity analyses tested model strength and parameter variability. RESULTS: Overall survival is decreased, and biliary complications and retransplantation are increased in recipients of DCD livers. Recipients of DBD livers gained 5.6 quality-adjusted life years (QALYs) at a cost of US$69 000/QALY, whereas recipients on the DBD + DCD LT waitlist gained 6.0 QALYs at a cost of US$61 000/QALY. The DBD + DCD organ strategy was superior to the DBD organ-only strategy. CONCLUSIONS: The extension of life and quality of life provided by DCD LT to patients on the waiting list who might otherwise not receive a liver transplant makes the continued use of DCD livers cost-effective.
Authors: Rosa Jurado; Isabel Morales; Diana Taboada; Francisca Denia; José Carlos Mingote; Miguel Ángel Jiménez; Tomás Palomo; Gabriel Rubio Journal: Psicothema Date: 2011-02
Authors: Derek Patel; Norah A Terrault; Francis Y Yao; Nathan M Bass; Uri Ladabaum Journal: Clin Gastroenterol Hepatol Date: 2005-01 Impact factor: 11.382
Authors: P R de Reuver; M A Sprangers; E A Rauws; J S Lameris; O R Busch; T M van Gulik; D J Gouma Journal: Endoscopy Date: 2008-08 Impact factor: 10.093
Authors: D E Schaubel; M K Guidinger; S W Biggins; J D Kalbfleisch; E A Pomfret; P Sharma; R M Merion Journal: Am J Transplant Date: 2009-04 Impact factor: 8.086
Authors: Raymond Vanholder; Beatriz Domínguez-Gil; Mirela Busic; Helena Cortez-Pinto; Jonathan C Craig; Kitty J Jager; Beatriz Mahillo; Vianda S Stel; Maria O Valentin; Carmine Zoccali; Gabriel C Oniscu Journal: Nat Rev Nephrol Date: 2021-05-05 Impact factor: 28.314
Authors: Felix Achana; Stavros Petrou; Jason Madan; Kamran Khan; Chen Ji; Anower Hossain; Ranjit Lall; Anne-Marie Slowther; Charles D Deakin; Tom Quinn; Jerry P Nolan; Helen Pocock; Nigel Rees; Michael Smyth; Simon Gates; Dale Gardiner; Gavin D Perkins Journal: Crit Care Date: 2020-09-27 Impact factor: 9.097